Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).

被引：16

作者：

DeMichele, Angela

Harding, James J.

Telli, Melinda L.

Munster, Pamela N.

McKay, Rana

Iliopoulos, Othon

Orford, Keith W.

Bennett, Mark K.

Mier, James Walter

Owonikoko, Taofeek Kunle

Patel, Manish R.

Carvajal, Richard D.

Meric-Bernstam, Funda

Infante, Jeffrey R.

机构：

[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Weill Cornell Med Coll, New York, NY USA

[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[5] Univ Calif San Francisco, San Francisco, CA 94143 USA

[6] Dana Farber Canc Inst, Boston, MA 02115 USA

[7] Harvard Med Sch, Boston, MA 02115 USA

[8] Harvard Med Sch, Charlestown, MA USA

[9] GlaxoSmithKline, Collegeville, PA USA

[10] Calithera Biosci Inc, San Francisco, CA USA

[11] Beth Israel Deaconess Med Ctr, Dana Farber Harvard Canc Ctr, Dept Med, Boston, MA USA

[12] Emory Univ, Atlanta, GA 30322 USA

[13] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA

[14] Columbia Univ, Med Ctr, New York, NY USA

[15] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Dept Surg Oncol,Phase 1 Program, Sheikh Khalifa Bin Zayed Al Nahyan Inst Personali, Houston, TX 77030 USA

[16] Sarah Cannon Res Inst, Nashville, TN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.1011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1011

引用

页数：2